Fact Checked
Fact Checked
This article has been fact checked by a licensed expert before publication to ensure all information provided is correct and safe.
Does Retatrutide affect periods differently to other GLP-1s?
Medically reviewed by
Sanjeda Chowdhury, Superintendent Pharmacist + Independent Prescriber
However, because weight can influence health – and reproductive health – in several ways, losing weight can affect your reproductive hormones and menstrual cycle.
And because Retatrutide is expected to be more effective and work differently to the existing weight loss medications on the market, the immediate effect that this weight loss can have on your menstrual cycle may be more pronounced.
How these treatments change your cycle
Changes in oestrogen levels
Fat cells actively produce oestrogen. So when weight loss medications help you lose weight quickly, this can cause short-term hormonal fluctuations in how much oestrogen your body produces. This means that while losing body fat ultimately lowers your baseline oestrogen in the long run, this quick transition may temporarily cause spotting, unpredictable flow, or brief flare-ups of endometriosis symptoms as your cycle adjusts.
Lower testosterone levels (in PMOS)
Some weight loss medications can also improve insulin sensitivity and reduce insulin levels. This has the effect of reducing testosterone levels, because excess insulin triggers your ovaries to produce too much testosterone. The upshot of this is that it can quickly restore regular ovulation, particularly if you have PMOS or PCOS. This sudden return of your cycle can mean a heavier flow at first as your body clears out built-up lining and, often, provides an unexpected fertility boost.
Reduced pill efficacy
Hormonal weight loss medications (especially Mounjaro (tirzepatide)) also slow down how quickly your stomach empties. This means that if you take a daily contraceptive pill, it might not absorb quite as well as it used to, which can lead to breakthrough bleeding or, more importantly, an increased chance of pregnancy as it becomes less effective. As a result, you should always use back-up contraception, like condoms, while you’re adjusting to a new dose.
Stress
How do Wegovy, Mounjaro and Retatrutide compare?
How does Retatrutide affect periods differently?
Retatrutide and endometriosis
Although retatrutide isn’t a direct treatment for endometriosis, it can still make an impact. The GLP-1 component helps quiet down inflammatory signalling, which may eventually ease symptoms like chronic pelvic pain or abdominal distension (‘endo belly’). And while you might experience a brief flare-up initially due to hormonal fluctuations, fat loss over the long-term should reduce overall oestrogen levels and ease inflammation.
Retatrutide and fertility
The improved insulin control and weight loss brought on by Retatrutide might help balance your hormones out. For many, this could mean a higher chance of getting pregnant. (And for men, dropping weight can boost testosterone, lifting sex drive and sperm count.) As a result, because of the way the drug affects pill absorption, and because rapid weight loss medications aren’t safe during pregnancy, using barrier contraception, like condoms, is a must if you’re able to conceive.
Retatrutide and heavy periods
Because retatrutide drives faster fat loss than other GLP-1s, initial hormone fluctuations may be more pronounced. And if you have PCOS, the initial resumption of ovulation can cause heavy flow during your first few cycles.
This is usually a temporary sign that your body is adapting, and your flow should lighten as your weight stabilises.
When might a period change be because of Retatrutide?
| What you might experience | When it’s time to see a doctor |
|---|---|
| Heavier periods (from hormone changes and the return of ovulation). | You’re having to change your pad or tampon every hour for two hours. |
| Periods arriving early, late, or skipping a month. | Your period lasts over 7 days, or you miss periods for two consecutive months. |
| Mild spotting between cycles. | You experience heavy, unexplained bleeding between periods. |
| Temporary endometriosis flare-ups. | Extreme pain that isn’t helped with pain killers. |
When will Retaturide be available in the UK?
The earliest realistic timeline for retatrutide to become available is 2028.
Retatrutide is an investigational drug that’s still undergoing late-stage (phase 3) clinical trials, known as the TRIUMPH programme. Its manufacturer, Eli Lilly, is expected to submit the final trial data to regulatory bodies for official review in early 2027.
Before retatrutide can be prescribed, it has to go through a couple of important steps:
- MHRA approval. The UK’s Medicines and Healthcare products Regulatory Agency will review the safety and effectiveness data. Once the MHRA grants a marketing license, doctors can prescribe it privately.
- NICE assessment. For retatrutide to be offered on the NHS, the National Institute for Health and Care Excellence (NICE) will need to evaluate its cost-effectiveness, which typically lengthens to the timeline.
But because retatrutide has been in the news so much, you might spot websites or social media sellers offering ‘retatrutide pens’ or vials. Retatrutide cannot be legally sold or prescribed for human use anywhere in the UK right now. Anything sold online claiming to be retatrutide is an unlicensed, unregulated research chemical and is not safe to use. The only lawful way to receive it at the moment is by participating in an official clinical trial.
If you’re looking for weight loss treatment now, you don’t have to wait for retatrutide. Proven treatments like Wegovy (semaglutide) and Mounjaro (tirzepatide) are already fully licensed, safe, and available now.
Reference Popover #ref1
Treated trusted source
Kuryłowicz, A. (2023).
Estrogens in adipose tissue physiology and obesity-related dysfunction. Biomedicines, 11(3), p.690.
Reference Popover #ref2
Treated trusted source
Campbell, K.L., et al. (2012).
Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: Randomized controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(19), pp.2314–2326.
Reference Popover #ref3
Treated trusted source
Nauck, M.A., Quast, D.R., Wefers, J. and Meier, J.J. (2021).
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46(46), p.101102.
Reference Popover #ref4
Treated trusted source
Unluhizarci, K., Karaca, Z. and Kelestimur, F. (2021).
Role of insulin and insulin resistance in androgen excess disorders. World Journal of Diabetes, 12(5), pp.616–629.
Reference Popover #ref5
Treated trusted source
NHS Westbury Group Practice (2025).
Impact of Weight Loss injections on contraception. Westburygrouppractice.nhs.uk.
Reference Popover #ref6
Treated trusted source
Kim, A.E., et al. (2025).
Caloric restriction, the menstrual cycle, and sleep in women without obesity. The Journal of Clinical Endocrinology & Metabolism, 110(11), pp.3108–3119.
Reference Popover #ref7
Treated trusted source
Wilding, J.P.H., Batterham, R.L. and Calanna, S. (2021).
Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), pp.989–1002.
Reference Popover #ref8
Treated trusted source
Jastreboff, A.M., et al. (2022).
Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), pp.205–216.
Reference Popover #ref9
Treated trusted source
Robertson, J. (2026).
Phase III retatrutide study demonstrates 30% weight loss. The Pharmaceutical Journal.
Reference Popover #ref10
Treated trusted source
Desai, S.N., Reed, C.C., Mendez, Y., Yang, Q. and Guan, X. (2026).
The hidden link between endometriosis and obesity: A state-of-the-art review. Cureus.
Reference Popover #ref11
Treated trusted source
Dearden, L. and Ozanne, S.E. (2025).
Incretin receptor agonism during pregnancy: Implications for mother and baby. Clinical science (London, England : 1979), 139(23), p.CS20258493.
Reference Popover #ref12
Treated trusted source
Okobi, O.E., et al. (2024).
Impact of weight loss on testosterone levels: A review of BMI and testosterone. Cureus.
Reference Popover #ref13
Treated trusted source
Eli Lilly and Company (2025).
Lilly’s triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C | Eli Lilly and company. Eli Lilly and Company.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Tell us what you want to hear.
Have a subject you’d like us to cover in a future article? Let us know.
Give us the inbox treatment.
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
Find treatment
I'm looking for
Popular searches:
Sign up to our newsletter for all the latest on and more.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.